Current Neuro-Oncology

Volume 28 Number 19
10 July 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 19, 10 July

Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke I, Wick W, Platten M.
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Nat Cancer. 2026 Jul 1. doi: 10.1038/s43018-026-01199-y. PMID: 42387024. Trial registration ID: NCT02454634. ˍ

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Sargos P, Taphoorn MJB, Vauleon E, Philips C, Kros JM, Bady P, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Jacob J, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Balana C, Azevedo ALS, Clement PM, Berghoff A, Tzuk-Shina T, Weller M, Nordal RA, Rees J, Lacombe DA, Mason WP, Stupp R.
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).
J Clin Oncol. 2026 Jul 2:JCO2502735. doi: 10.1200/JCO-25-02735. PMID: 42391581. Trial registration ID: EORTC 22033-26033˰ ˍ

Marciscano AE, Shih HA.
Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.
J Clin Oncol. 2026 Jul 2:JCO2600771. doi: 10.1200/JCO-26-00771. PMID: 42391595. ˍ

Lin J, Tang W, Li K, Chen Z, Zhang H, Ye Z, Li Z, Qu S, Huang G, Yi GZ.
Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection.
J Neurooncol. 2026 Jul 2;178(3):85. doi: 10.1007/s11060-026-05690-5. PMID: 42390632˰ ˍ

Linkowski L, Messing I, Berger M, Hollawell C, Friedes C, Alexander D, Wang X, Desai AS, Phillips RE, O'Rourke DM, Amankulor NM, Jackson C, Hubbeling H, Kurtz G, Bagley SJ, Bradley JD, Mohan S, Alonso-Basanta M, Lebow ES.
Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.
Int J Radiat Oncol Biol Phys. 2026 Jul 2:S0360-3016(26)03919-2. doi: 10.1016/j.ijrobp.2026.06.3058. PMID: 42392324. ˍ

Sharpe MA, Baskin AM, Teh BS, Butler EB, Baskin DS.
Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing.
J Neurooncol. 2026 Jul 3;178(3):88. doi: 10.1007/s11060-026-05685-2. PMID: 42397615. ˍ

Chen L, Li S, Wang L, Li H, Cai L, Lai M.
Fulminant extraneural metastases in MYC-amplified Group 3 medulloblastoma: a pediatric case report.
Childs Nerv Syst. 2026 Jul 4;42(1):284. doi: 10.1007/s00381-026-07351-4. PMID: 42399488. ˍ

Zhang Y, Chi X, Liu K, Ma Y, Zhang S, Ma X, Sun S, Zhang Y, Zhang K, Huang N, Cheng X, Ji N.
Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial.
Nat Commun. 2026 Jul 4. doi: 10.1038/s41467-026-75066-w. PMID: 42401550. Trial registration ID: NCT04968366. ˍ

Murakami K, Kijima N, Kuroda H, Tachi T, Ikeda S, Nakagawa K, Wada Y, Hagioka T, Hatanaka N, Hirayama R, Kishima H, Hosen N.
Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model.
Cancer Immunol Immunother. 2026 Jul 8. doi: 10.1007/s00262-026-04475-z. PMID: 42418010. ˍ

Nabors LB, Lobbous M, Han X, Fiveash J, Di Stasi A, Rochlin K, Oster R, Pillay T, Miller R, Chandrashekar DS, Ter Haak M, Ho W, Lamb LS Jr.
Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase-Expressing Lentivector in Patients With Primary Glioblastoma.
J Clin Oncol. 2026 Jul 8:JCO2502463. doi: 10.1200/JCO-25-02463. PMID: 42418736. Trial registration ID: NCT04165941˰ ˍ

Haresh KP, Thimmarayappa A, Roy S, Gupta S.
Timing of temozolomide in adult glioma: An exploratory study of an adaptive pre-radiotherapy approach in a mixed-grade cohort.
J Oncol Pharm Pract. 2026 Jul 9:10781552261451881. doi: 10.1177/10781552261451881. PMID: 42423607˰ ˍ

Paul G, Bjartmarz H, Kirkeby A, Nelander J, Smith R, Kayhanian S, Evans A, Harry B, Cutting E, Fazal S, Lao-Kaim NP, van Vliet T, Ullén S, Grubor I, Hansson O, Piccini P, Lindvall O, Björklund A, Widner H, Parmar M, Barker RA.
Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.
Nat Med. 2026 Jul 9. doi: 10.1038/s41591-026-04525-0. PMID: 42426223. Trial registration ID: NCT05635409. ˍ News

Mathews N, Jaffe A, McMichael K, Redjal N, Cardonick EH, Swanson TA, Kry SF, Salacz ME, Mann JM.
Magnetic Resonance Guided Radiation Therapy for High-Grade Glioma in Pregnancy: Planning, Validation, and Adaptive Fetal Dose Monitoring.
Adv Radiat Oncol. 2026 May 22;11(10):102099. doi: 10.1016/j.adro.2026.102099. PMID: 42382437. ˍ

Badran K, Robinson D, Ali A, Dherijha M.
Outcomes in spinal ependymoma: A retrospective analysis of 38 patients.
Surg Neurol Int. 2026 Jun 5;17:344. doi: 10.25259/SNI_1003_2025. PMID: 42404445. ˍ

Oxman L, Laviv Y.
Long-term survival in glioblastoma patients treated with dopamine agonists: A report of two cases and implications for drug repurposing.
Surg Neurol Int. 2026 Jun 5;17:340. doi: 10.25259/SNI_243_2026. PMID: 42404464. ˍ

Munlapudi V, Guzzino J, Crompton DJ, Agarwal S, Lehrer EJ, Kern S, Bogan A, Vora SA, Quinones-Hinojosa A, Burns TC, Sherman WJ, Brown PD, Laack N, Peterson J, Uhm JH, Ruff MW, Sener UT, Breen WG, Trifiletti DM.
Defining rapid early progression in glioblastoma-A volumetric approach.
Neurooncol Adv. 2026 Jun 8;8(1):vdag153. doi: 10.1093/noajnl/vdag153. PMID: 42382820. ˍ

Gurlek Tumer E, Tuysuz S, Yetisgin E, Guney Y.
Long-Term Survival in IDH-Wild-Type Glioblastoma: Clinical and Molecular Insights From Two Exceptional Cases.
Cureus. 2026 Jun 8;18(6):e110449. doi: 10.7759/cureus.110449. PMID: 42422637. ˍ

Main S, Swampillai A, Lavrador J, Al-Salihi O, Brazil L, Chia K, Manik V, Chin J, Clarke E, Reis Ferreira M.
Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.
Clin Oncol (R Coll Radiol). 2026 Jun 12;56:104209. doi: 10.1016/j.clon.2026.104209. PMID: 42385468. ˍ

Choi M, Choi Y, Lee J, Jeong SY, Kim M, Hwang I, Park JE, Park YW, Choi SH, Choi KS.
Distinguishing Molecular and Histologic Glioblastomas Using Multiparametric MRI-Based Habitat Analysis.
Korean J Radiol. 2026 Jun 23;27(7):670-681. doi: 10.3348/kjr.2025.1969. PMID: 42388098. ˍ

Scheer M, Prell J, Mawrin C, Leisz S, Schob S, Rampp S, Simmermacher S.
Not all enhancing lesions are tumor recurrence: Foreign body granulomas after glioma resection.
Brain Spine. 2026 Jun 23;6:106140. doi: 10.1016/j.bas.2026.106140. PMID: 42382657. ˍ

Li J, Hou L, Zhou H, Zhang Z, Wang Y, Zhan X, Wang W, Tian L, Xue X.
Postoperative clinical prognosis in 160 cases of glioblastoma and efficacy of vascular targeted therapy for recurrence.
Neoplasma. 2026 Jun 26:260306N56. doi: 10.4149/neo_2026_260306N56. PMID: 42429148. ˍ

Ozer BH, Lindhorst SM, Merrell RT, Trevino CR, Rudnick JD, Avgeropoulos NG, Ramakrishna N, Khagi S, Rauf Y, Walbert T, Pan E, Youssef M, Fink KL, Mandel JJ, Taylor LP, Colman H, Dunbar EM, Paleologos N, Burton EC, Wu J, Leeper HE, Gonzalez J, Penas-Prado M, Raizer JJ, Veglia E, Craig S, Yuan Y, Chambers C, Wall K, Grajkowska E, Mendoza T, Armstrong TS, Gilbert MR.
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
medRxiv [Preprint]. 2026 Jun 24:2026.06.22.26354817. doi: 10.64898/2026.06.22.26354817. PMID: 42396282. Trial registration ID: NCT03018288. ˍ

Gomez S, DiCioccio RA, Geiger AE, Grant ML, Reynolds E, Datar A, McCann CD, Tanna J, Kukadiya D, Hoq F, Zhang A, Hanley PJ, Webb JL, Kilburn LB, Rood BR, Fonseca A, Meany HJ, Vézina LG, Packer RJ, Cruz CRY, Bollard CM, Hwang EI.
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.
Nat Med. 2026 Jun 30. doi: 10.1038/s41591-026-04449-9. PMID: 42380677. Trial registration ID: NCT03652545. ˍ

Li W, Jiang S, Liu K, Li Z, Yang J, Liu W, Huang Y, Yang M, Guo S, Ruan S.
Exosome Secretion Drives Chemo-Resistance of Temozolomide in Glioblastoma.
J Extracell Biol. 2026 Jun 30;5(7):e70161. doi: 10.1002/jex2.70161. PMID: 42383157. ˍ